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1N 1957 Snell, in a review ofincompatibility reactions to tumour homotrains-
plantation, wrote
" The role ofcomplement wiR not be discussed ". Recent work
has shown that this attitude is no longer tenable. It has been shown that the
lytic action of humoral antibody on tumour ceRs in vitro is dependent on the
presence of complement (Flax, 1956; Lindner, 1960); and Winn (1960), dis-
cussing the action of antiserum onlymphoma ceRs in vivo, wrote, "-complement
can become a limiting factor in immune reactions allowed to proceed in vivo- ".
As it is now generally accepted that incompatibility reactions to tumour
transplantation are mediated through the host's immune response one would
expect the growth of a geneticaRy incompatible tumour transplant to be accom-
panied by a reduction in the serum complement level. The foRowing exp.eri-
merits were carried out to test this hypotbesis.
MATERIAL AND METHODS
Mice.-The mice used were of two types. Firstly mice from the closed
colony kept at this Institute (Hartveit, 1961) and secondly F, hybrids of these
mice (Y-) and mice of strainA/Sn All the mice were approximately 6 months
old.
Tumours.-Two ascitic tumours were used. The Ehrlich ascites carcinoma
that was transplanted in mice ofthe closed colony, and another ascitic carcinoma,
the Bergen A4 ascites carcinoma, that was derived from a strain A/Sn mouse at
this Institute (Hartveit, 1964a), and is transplanted in the F, hybrids described
above.
EXPERIMENTAL PROCEDURE
Non-tumour bearing mice.-Serum was obtained from 5 3 and 5 Y mice of the
closed colony and from 5 S and 5 Y F, hybrids.
Tumour bearing mice.-Serum and tumour ascitic fluid was taken from 5
and 5 Y mice of the closed colony 12 days after they had each been given an
intraperitoneal injection of 0-1 ml. of Ehrhch's ascites carcinoma. Serum and
ascitic fluid were also taken from 6 S and 4 Y F, hybrids 12 days after they had
been given a similar injection ofthe Bergen A4 ascites carcinoma. AR specimens
were stored at 20' C.
Titration of complementfactor CI.-The CI content of the serum and ascitic
fluid specimens was titrated. The method advised by Kabat and Meyer was
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foflowed (Kabat and Meyer, 1961), RI beingprepared by dialysis fromguinea-pig
serum. Specimens from both tumoux bearing and non-tumour bearing mice
were titrated from the same batch ofreagents.
RESULTS
Fig. I gives the Cl titre in tumour bearing mice and in mice without tumour.
The non-tumour bearing mice of the closed colony had a Cl titre of between
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FIG. I.-The complement factor I titre in the serum of mice with Ehrlich's ascites carcinoma
(EAC) and with Bergen A4 ascites carcinoma (BA4) and in niiee without tumour. See
text.
I : 32 and I : 128, with both mean and median at I : 64. The findings in the
non-tumour bearing F, hybrids were similar-but the scatter was even less-
8 out of 10 mice showing a titre of I : 64.
The tumour bearing mice, on the other hand, aR showed lower Cl titres-
between I : I and I : 16, with a composite median at I : 4. The scatter in the
mice with the Ehrlich ascites carcinoma was less than in those with the Bergen A4
ascites carcinoma, in which the titre also tended; on the whole, to be slightly
lower.
No clear sex differences were apparent.
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Fig. 2 compares the CI titre in the serum and the ascitic fluid of mice with
Ehrlich's ascites carcinoma and with the Bergen A4 ascites carcinoma, and shows
that there is little difference in the results in these two fluids or between the
results with these two tumours.
Asregards the differences between the two fluids, in 7 (3 Bergen and 4 Ehrhch)
there was no differeiice at all. There was a one tube difference in II cases (5
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Fi(:. 2.-The coi-iiplement factor I titre in the serum and ascitic fluid ofiiiice 12 days after tlle
iiitraperitoneal injection of Ehrlicb's ascites carcinoma and ofBergen A4 ascites carcinoma.
Bergen aiid 6 Ehrlich), in I0 of these (4 Bergen aiid 6 Ehrlich) the titre in the
ascitic fluid was lower than in the serum. In '2. cases (2 Bergen) there was a two
tube difference-in both of these the titre in the ascitic fluid was lower than that
in the serum.
The differences between the findiiigs with the two tumours show that the
teiidency to lower titres in the serum of mice with the Bergeii A4 ascites car-
ciiioma is also reflected in the ascitic fludd.
There were no marked sex differences.
DISCUSSION
In the present work the Cl content of mouse serum was titrated as this is the
oiily complement factor that is present in any appreciable amount in mouse
ser'Lim (Rice and Crowson, 1950; McGhee, 1952). In 1956 Gorer wrote,
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fortuiiately mouse serum has very peculiar properties ". These peculiar pro-
perties appear to lie, at least in part, in its complement content, which is said
to be active in vivo but not in vitro (Amos, 1961). Gorer, in the paper mentiolied
above, also comments on the difficulties of complementing mouse serum in vitro.
In the present work siich difficulty was not encountered when oiily the Cl was
titrated. Mouse serum has also been said to be anticomplementary (Rice and
Crowsoii, 1950) but this did not prove to be the case with the sera or ascitic fluids
used in the present experiments.
As CI is the first complement factor to be used up by sensitised cells in the
process ofimmunological lysis and as it will be used up whether the other factors
are present or not (Kabat and Meyer, 1961) the Cl level of the serum will be
independent of the level, presence or demonstrability of the other factors. In
addition, as immunehaemolysis isdependent on the titre ofthe complement factor
present in least concentration (Kabat and Meyer, 1961) the titration of Cl in
mouse serum, in the presence of RI, will not be effected by the minimal amounts
of the other complement factors that may be present in the serum.
The present experiments show that the Cl levels in non-tumour bearing mice,
of either sex, of the closed colony and of the F, hvbrids used were similar, with
a meaii titre of I : 64 (Fig. 1). The scatter of one tube in either directioii coiild
well be accounted for bv experimental error.
In contrast to these normal values are the titres obtained in tumour beariiig
mice wbich fall into a completely different range, as is shown in Fig. 1. After
12 davs of ascitic tumour growth.the Cl level of the serum had fallen to well
below the normal
" level in all cases. As an average of a four tube difference
in doubliiig dilutions is involved experimental error can be ruled out as- the cause
of the difference. On the other hand, it could be argued that
" dilution ", that
is to say an increase in the total extracellular fluid volume as a result of ascitic
fluid formation, may have led to this reduction in Cl titre. Further examination
of this possibility shows that it is uiilikely. For example if we take 20 per cent
of the total weight of a mouse as an estimate of its total extracellular fluid (Pitts.
1963) then aii average 25 g. mouse will contain 5 ml. extracellular fluid, which
in this case had a CI titre of I : 64 (if we take the mean titre). To re(luce this
titre to I : 4 (the mean tumour bearing titre) by dilution alone one would iieed a
mouse containing 80 ml. of extracellular fluid. This would indeed be an unlikely
situation as the ascitic fluid volume rarely exceeds 8 ml. in these mice. As about
40 per ceiit of this is tumour cells, the ascitic fluid itself would, if added to the
other extracellular fluid, give a figure ofapproximately 12 ml. Dilution to 12 ml.
would give about a one tube difference in reading. This degree of error lias
previousli- been accepted as
" experimental
" (vide supra). Therefore the drop
in Cl titre cannot be explained on the basis of dilution alone.
The differeiice in Cl titre in the serum and ascitic fluid in tumour beariiig mice
is not marked, but, when present, is consistently (apart from one case) in a down-
ward directioii, i.e. the titre in the ascitic fluid is lower than in the serum. This
differeiiee lies within the range ofexperimental error, but its consisteiicy makes it
suggestive. There also appear to be sligbtly lower Cl levels, both in the serum
and ascitic fluid, of mice with the Bergen A4 ascites carcinoma than in those
with Ehrlich's ascites carcinoma-but once again these differences are not signi-
ficant. On the whole the Cl level in these tumour bearing mice is remarkable
for its similaritv.
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Thus there are two maiii points for discussioii. Whv sliould the CI level
drop in tumour bearing mice, aiid why should it drop to a similar extent with the
Ehrlich ascites carcinoma and the Bergen A4 ascites carcinoma?
The answers to these two questions are closely interwoven aiid pose otlier
questions that are at present unanswered. Firstly, in vitro, the disappearaiice
of complement from a system is takeii as evidence of antigeii-antibody uiiioii.
Can we, without further ado, take the same standpoint to the disappearaiice of
complemeiit in vivo.? Naturally, the in vivo disappearance ofcomplement might
be a reflection of lack of production rather thaii of increased consumption. ff
so we must postulate that tumour growth is accompanied bv a fall in the produc-
tion ofCl. Otherwise we must accept in vitro experiei-ice and look for a source
of antigeii-antibody unioii in these tumour bearing mice.
In mice with the Ehrlich ascites carcinoma there is iiot far to look for the
possibility of such a reaction. The Ehrlich ascites careiiioma is a honiograft.
Therefore it is only to be expected that the host should brii-ig its immunological
defences to bear in its attempts to combat the foreign tissue.
Apart from the general conteiition that a homograft will provoke an immuiie,
response-which has been well documented in the past (Brei-it, 1958)-there is
also recent evidence that the tumour cells in the case of the Ehrlich ascites car-
cinoma provoke an immuiie response (Hartveit, 1963) aiid are, in fact, seiisitised
cells (Hartveit, 1965a, b). If the cells are sensitised-i.e. antibody coated-it is
reasonable that they should adsorb complement. The findiiigs in the preseiit
work thus support the earlier circumstantial evidence of aii immune response to
this homograft.
The position as regards the Bergeii A4 ascites carcinoma, however, is differeiit.
This tumour arose in an inbred mouse and istransplanted ingeneticallycompatible
mice. It has been carried as a transplanted tumour for only a short time (20
transplant generations). So, thougli mutation of course cannot be ruled out
it is unlikely-particularly as no change in the behaviour of the tumour has
occurred. In addition, mutations in transplantable tumours usually lead to
loss rather than gain in antigenicity (Hauschka and Amos, 1957). Thus. from
theimmunogeneticist'spoint ofview, this tumour should iiot provoke anv immuiie
response oii transplantation in the mice used in the preseiit work. But, even so.
to the tumour immunologist such a response would not be out of place. While
the former would hold that the response to normal and tumour tissue oii trans-
plantation is the same, and that variations must be due to experimental error,
the latter would be awake to the possibility that the presence of tumour specific
ai-itigen in the tumour might lead to antigeiiie differences in an otherwise com-
patible system.
As with the Ehrlich ascites carcinoma there is eircumstaiitial evidence that
iiidicates that growth of the Bergeii A4 ascites carcinoma is accompanied by ali
immune response on the part of the host-in this case the seemiilgly genetically compatible host. This evidence lies in the finding that growth of this tumotir
is accompanied by iiitraperitoneal liaemorrhage (Hartveit. 1.464a) aiid also that
the cells behave as sensitised cells when treated with fresh humaii serum (Hart-
veiti 1964b).
Measurements of the (11 level in mice with iioii-tumour homografts, as opposed
to genetically compatible grafts have so far failed to reveal aiiy changes in titre
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as thev are not trtilv comparable. Preliminary experiments to the preseilt work
showe4 that in this test system differences in the Cl titre could not be determined
with certaintv before 7 days after transplantation wheii tumour growth was well
established. A graft of noi-i-tumour tissue does not proliferate to the same exteiit
as tumour tissue aiid so theantigenic stimulus itmight represent is not comparable
at a time wheii a difference in Cl level could be expected. Incidentally it has iiot
proved possible to demonstrate a drop in Cl level in mice with subcutaneous
tumour transplants.
So the fiiidiiig that the growth of the Bergeii A4 ascites carcinoma as well as
the Ehrlieb ascites carcinoma leads to a drop in Cl level could be interpreted in
two ways. The drop in botb cases may be a reflection of an immune respoiise
on the part of the host : in the latter an immune response to homografted tissue,
in the former aii immuiie response to a tumour specific antigeii in an otherwise
geiieticallv compatible system. Oii the other hand, the drop in Cl level may
have iiothing to do with the host's immune response and merely be a reflection
of decreased productioii of Cl as mentioned above. Therefore the aetiology of
the drop in Cl level in tumour bearing mice described here is, perhaps, questioii-
able-but the fiiiding provides further evideiice in support of the view that com-
plemeiit must be taken into consideration in studies on tumour transplantation,
aiid that tumour immuiiity, in addition to transplaiitation immuiiitv, miist be
coiisidered in transplaiitatioi-i studies.
SUMMARY
The CI level in mice beariiig 12daytransplaiits ofthe Ehrlich ascites careiiioma
aiid of rnice bearing a geiietically compatible ascitic carcinoma (the Bergen A4
ascites carcinoma) was shown to be lower than that of non-tumour bearing mice.
It is suggested that, in the former case, this is evidence that complement has been
used up bv the homografted cells that have become sensitised in vivo. In the
latter case the drop in complement titre poses the question as to whether the
tumour cells in this system are also seiisitised. If so this could be regarded as
evidence of the preseiiee of tumour specific antibodv. and heiiee tumour specific
antigen.
My thanks are due to Professor E. Waaler. Head of this Iiistitute, for the
iiiterest he has showii in this work. I would also like to thaiik Miss L. Wills foi-
her technical assistaiiee.
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